Physician profile
Libby Buscemi
NPI 1710044599
$5,972.32
in general payments reported to CMS, 2019-2025
30 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $203 · 2021: $732 · 2022: $907 · 2023: $942 · 2024: $792 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.25 |
| Education | $189.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.97 | 2019-2025 | Rinvoq, Skyrizi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $935.67 | 2019-2025 | Jublia, Cabtreo |
| Janssen Biotech, INC. | $545.17 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $452.77 | 2019-2025 | |
| Incyte Corporation | $357.52 | 2021-2025 | Opzelura |
| Amgen INC. | $329.21 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $327.61 | 2019-2025 | |
| Galderma Laboratories, L.P. | $303.08 | 2019-2025 | Aklief, Nemluvio |
| Sun Pharmaceutical Industries INC. | $302.48 | 2019-2025 | |
| Genzyme Corporation | $203.81 | 2019-2024 | |
| Lilly USA, LLC | $195.70 | 2020-2025 | Olumiant, Ebglyss, Taltz |
| Dermavant Sciences, INC. | $184.12 | 2023 | Vtama |
| Leo Pharma INC. | $151.00 | 2019-2024 | Adbry |
| Almirall LLC | $97.35 | 2019-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $81.76 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.59 | 2019 | |
| Mayne Pharma Commercial LLC | $59.66 | 2019-2023 | |
| Journey Medical Corporation | $58.62 | 2022-2023 | |
| Lnhc, INC | $48.10 | 2025 | Zelsuvmi |
| E.R. Squibb & Sons, L.L.C. | $43.52 | 2022-2024 | Sotyktu |
| Allergan, INC. | $40.33 | 2019 | |
| Vyne Pharmaceuticals INC. | $34.03 | 2021 | |
| Epi Health, LLC | $33.96 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $33.23 | 2025 | Dupixent |
| Botanix Sb INC | $28.00 | 2025 | Sofdra |
| Hologic Sales and Service, LLC | $25.72 | 2021 | |
| Aclaris Therapeutics, INC. | $22.22 | 2019 | |
| Ucb, INC. | $22.22 | 2023 | Cimzia |
| Kyowa Kirin, INC. | $17.03 | 2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $13.87 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Buscemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.